<DOC>
	<DOCNO>NCT00006255</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation use high-frequency electric current heat kill tumor cell . Magnetic resonance imaging-guided radiofrequency ablation may effective treatment primary kidney cancer , liver metastasis , solid tumor . PURPOSE : Phase II trial study effectiveness magnetic-resonance-guided radiofrequency ablation treat patient primary kidney cancer , liver metastasis , solid tumor .</brief_summary>
	<brief_title>Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation Primary Renal Cell Carcinoma , Hepatic Metastasis , Other Sites Solid Organ Tumor Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether magnetic resonance image monitoring radiofrequency interstitial thermal ablation accurately predict complete destruction focal tumor along adequate margin normal tissue , demonstrate absence growth subsequent imaging study 1-year period , patient primary renal cell carcinoma , hepatic metastasis , solid tumor . OUTLINE : Patients stratify accord disease ( localize hepatic metastasis vs primary renal neoplasm vs solid tumor site ) . Patients undergo thermal ablation radiofrequency energy magnetic resonance guidance . Thermal ablation continue entire tumor treat . Treatment cease entire lesion undergone necrosis zone necrosis significant heat deposition approach vital neurovascular structure . Patients follow 2 week 3 , 6 , 9 , 12 month . PROJECTED ACCRUAL : A total 28-39 patient accrue study within 22-36 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary renal cell carcinoma , hepatic metastasis , solid tumor meeting follow criterion : Not amenable curative substantial palliative therapy OR Failed chemotherapy biological response modifier therapy OR Unlikely benefit conventional chemotherapy No 5 measurable metastatic mass liver No great 5 cm diameter Other tumor site allow location size amenable ablation therapy Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 4 month Hematopoietic : Granulocyte count least 1,000/mm^3 Hemoglobin least 8.0 g/dL Platelet count least 100,000/mm^3 No untreated bleed diathesis Hepatic : PT great 13.5 second PT/PTT normal prior warfarin heparin use Renal : Not specify Cardiovascular : No implanted pacemaker , incompatible aneurysm clip , device would preclude magnetic resonance image No myocardial infarction within past 6 week No unstable angina Other : Not pregnant nursing No serious active infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 28 day since prior biological response modifier therapy Chemotherapy : See Disease Characteristics At least 28 day since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy study lesion Surgery : Not specify Other : At least 7 day since prior nonsteroidal antiinflammatory drug aspirin At least 1 hour since prior heparin No concurrent warfarin No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>liver metastasis</keyword>
</DOC>